Myelodysplastic syndrome (MDS) is a heterogeneous hematological neoplasm with a wide range of clinical presentations from isolated anemia to pancytopenia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone marrow dysplasia and ineffective hematopoiesis resulting from a range of cytogenetic abnormalities and somatic gene mutations. Disease management varies from observation alone for low-risk disease to hypomethylating agents and hematopoietic cell transplantation (HCT) for higher risk disease. In this chapter, we review the classification, risk stratification, and optimal management of patients with MDS.
Keywords: 2 (MDS-EB1; 5q- syndrome; Allogeneic hematopoietic cell transplant (alloHCT); EB2); Hypomethylating agents; Myelodysplastic syndrome (MDS); Myelodysplastic syndrome with excess blast 1.
© 2021. Springer Nature Switzerland AG.